BHC BHC ボシュ・ヘルス・カンパニ―ズ

 BHCのチャート


 BHCの企業情報

symbol BHC
会社名 Bausch Health Companies Inc (BHC ボシュ・ヘルス・カンパニ―ズ)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 バウシュ・ヘルス・カンパニズ(Bausch Health Companies Inc)(旧名:Valeant Pharmaceuticals International Inc)は医薬品、医療機器および市販商品を開発、製造、販売するカナダ会社である。同社は主に目の健康、消化器、皮膚科の治療分野で製品を開発する。皮膚科製品は光線性角化症、座瘡、アトピー性皮膚炎、乾癬および他の皮膚病を治療する。また、顔のしわ、にきび、色素沈着、レーザー脱毛などの症状に対応する美容医療機器の選択肢も提供する。胃腸(GI)セグメントはGIおよび肝性脳症、下痢および潰瘍性大腸炎を伴う過敏性腸症候群を含む肝臓病態を治療する製品を提供する。目の健康製品は、コンタクトレンズ、医薬品および外科などのカテゴリーで販売される。  バレアント・ファ―マシュ―ティカルズ・インタ―ナショナルは、カナダ医薬品・医療機器メ―カ―。医薬品、市販薬、コンタクトレンズ・眼内レンズ・眼科手術用機器を含む医療機器の開発、製造、販売に従事する。事業は、市場開発と新興成長市場に分かれ、米国、プエルトリコ、カナダ、ポ―ランド、ロシアで販売する。  Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.
本社所在地 514 744-6792
代表者氏名 Joseph C. Papa
代表者役職名 Chairman of the Board Chief Executive Officer
電話番号 +1 514-744-6792
設立年月日 1987年
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 21100人
url www.bauschhealth.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 3318.00000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 8672.64400
売上高 売上高(百万ドル) 8380.00000
企業価値(EV) 企業価値(EV)(百万ドル) 32256.64400
当期純利益 当期純利益(百万ドル) -4148.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Bausch Health Companies Inc revenues decreased 4% to $8.38B. Net loss before extraordinary items totaled $4.15B vs. income of $1.43B. Revenues reflect Bausch + Lomb / International segment decrease of 4% to $4.66B U.S. Diversified Products segment decrease of 3% to $1.34B United States and Puerto Rico segment decrease of 4% to $5.01B Other Foreign Countries segment decrease of 11% to $1.04B.

 BHCのテクニカル分析


 BHCのニュース

   Tesco and Asda urgently recall contact lens solution over chemical fault bring it back  2021/06/11 06:50:15 SimpleNews
SimpleNews Tesco and Asda urgently recall contact lens solution over chemical fault bring it back A product recall is issued when there is a discovery made about a certain product that is deemed unsafe to the consumer. The latest recall comes from Tesco and Asda who are recalling certain contact lens solutions. The company said the recall was voluntary. In a separate recall, Asda also issued a warning about Bausch [] The post Tesco and Asda urgently recall contact lens solution over chemical fault bring it back appeared first on SimpleNews .
   Rx Irritable Bowel Syndrome (IBS) Drugs Market 2021 2027 | Growth Dynamics, Revenue Outlook and Opportunities Forecast Bausch Health, Takeda, Sebela Pharmaceuticals  2021/06/10 15:48:00 OpenPR
QY Research offers its latest report on the global Rx Irritable Bowel Syndrome (IBS) Drugs market that includes a comprehensive analysis on a range of subjects such as competition, segmentation, regional expansion, and market dynamics. Los Angeles, United States: The report
   Bausch + Lomb Signs Deal With Lochan to Develop New eyeTELLIGENCE Clinical Decision Support Software  2021/06/08 15:38:51 Smarter Analyst
Bausch + Lomb, a global eye health business owned by Bausch Health Companies Inc. (BHC), announced Tuesday that it has signed a deal with Lochan LLC. The post Bausch + Lomb Signs Deal With Lochan to Develop New eyeTELLIGENCE Clinical Decision Support Software appeared first on Smarter Analyst .
   Global Plastic Surgery Devices Market 2021:Size, Industry Status and Growth opportunities,Competitive Outlook,Forecast To 2028||ADODERM GmbH, Bioha Laboratories, Surgisil LLP, Solta Medical (A Subsidiary of Bausch Health Companies Inc.), B. Braun Melsunge  2021/06/08 07:20:22 OpenPR
Global plastic surgery devices market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 10.1% in the forecast period of 2021
   Obligatie Bausch Health 5% 2029 per 2.000 dollar krabbelt overeind  2021/06/08 05:48:00 Investing.com Netherlands
https://nl.investing.com/analysis/obligatie-bausch-health-5-2029-per-2000-dollar-krabbelt-overeind-200205375
   Bausch Health Reports Wider Q1 Loss, Hit By Impairment Charges On Ortho Dermatologics  2021/05/04 13:14:06 Benzinga
Bausch Health Companies Inc (NYSE: BHC ) reported a deeper first-quarter loss of $610 million compared with a loss of US$152 million a year earlier, impacted by a $469 million goodwill impairment charge in its Ortho Dermatologics business and a $71-million impairment charge related to a product line in Ortho Dermatologics. On an adjusted basis, Bausch Health earned $370 million for the quarter, up from an adjusted profit … Full story available on Benzinga.com
   Bausch Health Exploring Potential Divestiture Of Eye Care Units: Bloomberg  2021/04/29 16:36:03 Benzinga
Bausch Health Companies Inc (NYSE: BHC ) said in August that it would spin off its eye-care unit and operate it as an independent, publicly traded company. As a standalone company, Bausch + Lomb could be valued at $20 billion to $30 billion, according to Bloomberg Intelligence . The business has attracted interest from private … Full story available on Benzinga.com
   Abu Dhabi's ADQ Expands Healthcare Investments With Amoun Pharmaceuticals Acquisition From Bausch Health For $740M  2021/03/31 17:20:19 Forbes Middle East

Bausch Health Companies Inc, a Canadian drugmaker, announced that it would sell its entire interest in Egyptian drug developer Amoun Pharmaceutical Co SAE to Abu-Dhabi-based ADQ for $740 million with certain debt adjustments.

   Acne Treatment Market | Industry Analysis, Market Trends, Opportunities, and Forecast 2025 | Foamix Pharmaceuticals Ltd., Bausch Health Companies Inc. (Formerly Valeant Pharmaceuticals), Nestle (Galderma S.A.) and Allergan (Actavis Plc)  2021/03/22 13:03:06 OpenPR
MarketReportsOnline.com the exclusive leading provider of market research reports published research report on “Global Acne Treatment Market: Size, Trends & Forecasts (2021-2025 Edition)”. The report entitled “Global Acne Treatment Market: Size, Trends & Forecasts (2021-2025 Edition)”, provides an analysis of the
   2 Top Canadian Value Stocks That Could Skyrocket Into Year’s End  2021/03/22 12:54:18 The Motley Fool Canada
Bausch Health Companies Inc.(TSX:BHC)(NYSE:BHC) and Bank of Montreal (TSX:BMO)(NYSE:BMO) are two Canadian value stocks to consider. The post 2 Top Canadian Value Stocks That Could Skyrocket Into Year’s End appeared first on The Motley Fool Canada .
   Warren Buffett: I’d Follow Him Into This Defensive Industry  2021/01/07 17:00:49 The Motley Fool Canada
Bausch Health Companies (TSX:BHC)(NYSE:BHC) is one Canadian way to follow Warren Buffett into the defensive healthcare industry. The post Warren Buffett: I’d Follow Him Into This Defensive Industry appeared first on The Motley Fool Canada .
   Bausch Health To Participate At The 39th Annual J.P. Morgan Healthcare Conference  2021/01/06 12:00:00 PR Newswire
LAVAL, QC, Jan. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 10:00 a.m. ET. A…
   Impact of COVID-19 on Vaginal Fungi Infections Treatment Market SWOT Analysis by 2027 | Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals  2021/01/05 11:00:51 OpenPR
The latest 100+ page survey report on Vaginal Fungi Infections Treatment Market is released by CMI covering various players of the industry selected from global geographies like North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe
   Global Lassa Fever Treatment Market Current Trends And Future Aspect Analysis 2027| | Top Companies-Zydus Pharmaceuticals, Inc., Aurobindo Pharma., Bausch Health Companies Inc. and Navinta LLC., Three Rivers Pharmaceuticals LLC  2021/01/05 10:23:12 OpenPR
Global Xyz Market describes complete industry Outlook with in-depth analysis. This report also Includes the complete analysis of each segment in terms of opportunity, market attractiveness index and growth rate, top players and new comers in industry, competitive landscape, sales,
   Bausch Health's DEXAVEN (Dexamethasone Phosphate) Receives New Indication In Poland To Treat Patients With SARS-CoV-2 (COVID-19)  2020/12/30 12:00:00 PR Newswire
LAVAL, QC, Dec. 30, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland has granted an additional new indication for DEXAVEN…

 関連キーワード  (医薬品 米国株 BHC ボシュ・ヘルス・カンパニ―ズ BHC )

 twitter  (公式ツイッターやCEOツイッターなど)